Global Blood Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Global Blood Therapeutics generated cash of -$256,813,000, which is less than the previous year. Cash used in financing activities reached the amount of $434,335,000 last year. Net change in cash is therefore $189,951,000.
Cash Flow
| 2013 | -14.7M | -940K | 15.27M |
|---|---|---|---|
| 2014 | -20.12M | -383K | 69.29M |
| 2015 | -30.89M | -993K | 128.31M |
| 2016 | -67.72M | -106.85M | 118.14M |
| 2017 | -93.02M | -35.90M | 235.18M |
| 2018 | -135.37M | -184.15M | 397.90M |
| 2019 | -194.41M | -76.86M | 298.15M |
| 2020 | -211.86M | 317.31M | 87.12M |
| 2021 | -256.81M | 12.11M | 434.33M |
GBT Cash Flow Statement (2013 – 2021)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 497.20M | 304.63M | 277.75M | 199.37M | 92.07M | 148.50M | 52.06M | 3.27M | 3.63M |
Operating activities | |||||||||
Net income | -303.09M | -247.55M | -266.76M | -174.19M | -117.02M | -82.46M | -46.36M | -20.80M | -18.11M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 8.61M | 10.82M | 9.93M | 4.60M | 1.65M | 1.23M | 873K | 666K | 534K |
Stock-based compensation expense | 78.67M | 71.47M | 45.65M | 30.08M | 13.68M | 9.23M | 3.22M | 350K | 138K |
| Deferred income tax benefit | 78.67M | 71.47M | 45.65M | 30.08M | 13.68M | 9.23M | 3.22M | 350K | 138K |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | -11.3M | -14.86M | -2.63M | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | -16.14M | -36.77M | -1.27M | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -3.72M | 8.37M | 4.49M | -1.28M | 2.77M | 1.06M | 2.70M | -304K | -465K |
Cash generated by operating activities | -256.81M | -211.86M | -194.41M | -135.37M | -93.02M | -67.72M | -30.89M | -20.12M | -14.7M |
Investing activities | |||||||||
Purchases Of Investments | -50.35M | -57.93M | -434.91M | -361.40M | -127.72M | -105.5M | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -3.23M | -8.75M | -3.46M | -4.82M | -3.10M | -1.35M | -993K | -323K | -940K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 12.11M | 317.31M | -76.86M | -184.15M | -35.90M | -106.85M | -993K | -383K | -940K |
Financing activities | |||||||||
Common Stock Issued | 46.14M | 0 | 219.44M | 396.50M | 231.95M | 116.99M | 128.33M | 0 | 43K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | -12K | -421K | -90K | -67K | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 434.33M | 87.12M | 298.15M | 397.90M | 235.18M | 118.14M | 128.31M | 69.29M | 15.27M |
Net Change In Cash | 189.95M | 192.57M | 26.88M | 78.37M | 106.26M | -56.43M | 96.43M | 48.79M | -361K |
Cash at end of period | 687.15M | 497.20M | 304.63M | 277.75M | 198.33M | 92.07M | 148.50M | 52.06M | 3.27M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |